{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:05:36Z","timestamp":1762607136051},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T00:00:00Z","timestamp":1510531200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00347-017-0608-6","type":"journal-article","created":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T12:52:37Z","timestamp":1510577557000},"page":"100-106","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Neue aktuelle und zuk\u00fcnftige Therapieoptionen in der Behandlung des trockenen Auges"],"prefix":"10.1007","volume":"115","author":[{"given":"E. M.","family":"Messmer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,11,13]]},"reference":[{"key":"608_CR1","first-page":"71","volume":"112","author":"EM Messmer","year":"2015","unstructured":"Messmer EM (2015) The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int 112:71\u201381 (quiz 82)","journal-title":"Dtsch Arztebl Int"},{"key":"608_CR2","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/00003226-199811000-00002","volume":"17","author":"ME Stern","year":"1998","unstructured":"Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC (1998) The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 17:584\u2013589","journal-title":"Cornea"},{"key":"608_CR3","first-page":"6","volume":"92","author":"A Heiligenhaus","year":"1995","unstructured":"Heiligenhaus A, Koch JM, Kruse FE, Schwarz C, Waubke TN (1995) Diagnosis and and differentiation of dry eye disorders. Ophthalmologe 92:6\u201311","journal-title":"Ophthalmologe"},{"key":"608_CR4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/ICO.0b013e318225415a","volume":"31","author":"MA Lemp","year":"2012","unstructured":"Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD (2012) Distribution of aqueous-deficient and evaporative dry eye in a\u00a0clinic-based patient cohort: a\u00a0retrospective study. Cornea 31:472\u2013478","journal-title":"Cornea"},{"key":"608_CR5","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1167\/iovs.09-4445","volume":"51","author":"L Tong","year":"2010","unstructured":"Tong L, Chaurasia SS, Mehta JS, Beuerman RW (2010) Screening for meibomian gland disease: its relation to dry eye subtypes and symptoms in a\u00a0tertiary referral clinic in singapore. Invest Ophthalmol Vis Sci 51:3449\u20133454","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"608_CR6","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones L, Downie LE, Korb D et\u00a0al (2017) TFOS DEWS II management and therapy report. Ocul Surf 15:575\u2013628","journal-title":"Ocul Surf"},{"key":"608_CR7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.5301\/ejo.5000355","volume":"24","author":"S Barabino","year":"2014","unstructured":"Barabino S, Rolando M, Nardi M, Bonini S, Aragona P, Traverso CE (2014) The effect of an artificial tear combining hyaluronic acid and tamarind seeds polysaccharide in patients with moderate dry eye syndrome: a\u00a0new treatment for dry eye. Eur J Ophthalmol 24:173\u2013178","journal-title":"Eur J Ophthalmol"},{"key":"608_CR8","first-page":"157","volume":"8","author":"S Cohen","year":"2014","unstructured":"Cohen S, Martin A, Sall K (2014) Evaluation of clinical outcomes in patients with dry eye disease using lubricant eye drops containing polyethylene glycol or carboxymethylcellulose. Clin Ophthalmol 8:157\u2013164","journal-title":"Clin Ophthalmol"},{"key":"608_CR9","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jcrs.2012.02.040","volume":"38","author":"D Diaz-Valle","year":"2012","unstructured":"Diaz-Valle D, Arriola-Villalobos P, Garcia-Vidal SE et al (2012) Effect of lubricating eyedrops on ocular light scattering as a\u00a0measure of vision quality in patients with dry eye. J\u00a0Cataract Refract Surg 38:1192\u20131197","journal-title":"J Cataract Refract Surg"},{"key":"608_CR10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jtos.2013.11.002","volume":"12","author":"MJ Doughty","year":"2014","unstructured":"Doughty MJ (2014) Fluorescein-tear breakup time as an assessment of efficacy of tear replacement therapy in dry eye patients: a\u00a0systematic review and meta-analysis. Ocul Surf 12:100\u2013111","journal-title":"Ocul Surf"},{"key":"608_CR11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/ICO.0b013e3181e9adcc","volume":"30","author":"JH Lee","year":"2011","unstructured":"Lee JH, Ahn HS, Kim EK, Kim TI (2011) Efficacy of sodium hyaluronate and carboxymethylcellulose in treating mild to moderate dry eye disease. Cornea 30:175\u2013179","journal-title":"Cornea"},{"key":"608_CR12","doi-asserted-by":"crossref","first-page":"7977","DOI":"10.1167\/iovs.13-11798","volume":"54","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Potvin R, Gong L (2013) A study of the short-term effect of artificial tears on contrast sensitivity in patients with Sjogren\u2019s syndrome. Invest Ophthalmol Vis Sci 54:7977\u20137982","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"608_CR13","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5001011","author":"EI Postorino","year":"2017","unstructured":"Postorino EI, Rania L, Aragona E et al (2017) Efficacy of eyedrops containing cross-linked hyaluronic acid and coenzyme Q10 in treating patients with mild to moderate dry eye. Eur J Ophthalmol. \n                        https:\/\/doi.org\/10.5301\/ejo.5001011","journal-title":"Eur J Ophthalmol"},{"key":"608_CR14","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1001\/jamaophthalmol.2013.2385","volume":"131","author":"TA Schmidt","year":"2013","unstructured":"Schmidt TA, Sullivan DA, Knop E et\u00a0al (2013) Transcription, translation, and function of lubricin, a\u00a0boundary lubricant, at the ocular surface. JAMA Ophthalmol 131:766\u2013776","journal-title":"JAMA Ophthalmol"},{"key":"608_CR15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1186\/s13075-015-0877-x","volume":"17","author":"A Alquraini","year":"2015","unstructured":"Alquraini A, Garguilo S, D\u2019Souza G et al (2015) The interaction of lubricin\/proteoglycan 4 (PRG4) with toll-like receptors 2 and 4: an anti-inflammatory role of PRG4 in synovial fluid. Arthritis Res Ther 17:353","journal-title":"Arthritis Res Ther"},{"key":"608_CR16","doi-asserted-by":"crossref","first-page":"18910","DOI":"10.1038\/srep18910","volume":"6","author":"SM Iqbal","year":"2016","unstructured":"Iqbal SM, Leonard C, Regmi SC et al (2016) Lubricin\/Proteoglycan 4 binds to and regulates the activity of toll-like receptors in vitro. Sci Rep 6:18910","journal-title":"Sci Rep"},{"key":"608_CR17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jtos.2016.08.004","volume":"15","author":"A Lambiase","year":"2017","unstructured":"Lambiase A, Sullivan BD, Schmidt TA et al (2017) A two-week, randomized, double-masked study to evaluate safety and efficacy of Lubricin (150 mug\/mL) eye drops versus sodium hyaluronate (HA) 0.18\u202f% eye drops (Vismed(R)) in patients with moderate dry eye disease. Ocul Surf 15:77\u201387","journal-title":"Ocul Surf"},{"key":"608_CR18","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/eye.2012.166","volume":"26","author":"K Kamiya","year":"2012","unstructured":"Kamiya K, Nakanishi M, Ishii R et\u00a0al (2012) Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a\u00a0prospective, randomized, multicenter study. Eye (Lond) 26:1363\u20131368","journal-title":"Eye (Lond)"},{"key":"608_CR19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s10384-013-0251-y","volume":"57","author":"S Koh","year":"2013","unstructured":"Koh S, Ikeda C, Takai Y, Watanabe H, Maeda N, Nishida K (2013) Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye. Jpn J Ophthalmol 57:440\u2013446","journal-title":"Jpn. J. Ophthalmol."},{"key":"608_CR20","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.ophtha.2012.04.010","volume":"119","author":"Y Matsumoto","year":"2012","unstructured":"Matsumoto Y, Ohashi Y, Watanabe H, Tsubota K (2012) Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a\u00a0Japanese phase 2 clinical trial. Ophthalmology 119:1954\u20131960","journal-title":"Ophthalmology"},{"key":"608_CR21","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12325-012-0033-9","volume":"29","author":"M Nakamura","year":"2012","unstructured":"Nakamura M, Imanaka T, Sakamoto A (2012) Diquafosol ophthalmic solution for dry eye treatment. Adv Ther 29:579\u2013589","journal-title":"Adv Ther"},{"key":"608_CR22","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1097\/ICO.0b013e3182930b1d","volume":"32","author":"S Shimazaki-Den","year":"2013","unstructured":"Shimazaki-Den S, Iseda H, Dogru M, Shimazaki J (2013) Effects of diquafosol sodium eye drops on tear film stability in short BUT type of dry eye. Cornea 32:1120\u20131125","journal-title":"Cornea"},{"key":"608_CR23","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/bjophthalmol-2011-301448","volume":"96","author":"E Takamura","year":"2012","unstructured":"Takamura E, Tsubota K, Watanabe H, Ohashi Y (2012) A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol 96:1310\u20131315","journal-title":"Br J Ophthalmol"},{"key":"608_CR24","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ajo.2013.11.010","volume":"157","author":"S Kinoshita","year":"2014","unstructured":"Kinoshita S, Awamura S, Nakamichi N, Suzuki H, Oshiden K, Yokoi N (2014) A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye. Am J Ophthalmol 157:576\u2013583.e1","journal-title":"Am. J. Ophthalmol."},{"key":"608_CR25","doi-asserted-by":"crossref","first-page":"6265","DOI":"10.1167\/iovs.10-6220","volume":"52","author":"S Samudre","year":"2011","unstructured":"Samudre S, Lattanzio FA Jr., Lossen V et\u00a0al (2011) Lacritin, a\u00a0novel human tear glycoprotein, promotes sustained basal tearing and is well tolerated. Invest Ophthalmol Vis Sci 52:6265\u20136270","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"608_CR26","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1167\/iovs.14-13924","volume":"55","author":"T Vijmasi","year":"2014","unstructured":"Vijmasi T, Chen FY, Balasubbu S et al (2014) Topical administration of lacritin is a\u00a0novel therapy for aqueous-deficient dry eye disease. Invest Ophthalmol Vis Sci 55:5401\u20135409","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"608_CR27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/IIO.0000000000000163","volume":"57","author":"K Gumus","year":"2017","unstructured":"Gumus K, Pflugfelder SC (2017) Intranasal tear neurostimulation: an emerging concept in the treatment of dry eye. Int Ophthalmol Clin 57:101\u2013108","journal-title":"Int Ophthalmol Clin"},{"key":"608_CR28","first-page":"218","volume":"45","author":"D Hyden","year":"2007","unstructured":"Hyden D, Arlinger S (2007) On the sneeze-reflex and its control. Rhinology 45:218\u2013219","journal-title":"Rhinology"},{"key":"608_CR29","first-page":"795","volume":"10","author":"NJ Friedman","year":"2016","unstructured":"Friedman NJ, Butron K, Robledo N, Loudin J, Baba SN, Chayet A (2016) A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease. Clin Ophthalmol 10:795\u2013804","journal-title":"Clin Ophthalmol"},{"key":"608_CR30","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1167\/iovs.16-21362","volume":"58","author":"M Brinton","year":"2017","unstructured":"Brinton M, Kossler AL, Patel ZM et\u00a0al (2017) Enhanced tearing by electrical stimulation of the anterior ethmoid nerve. Invest Ophthalmol Vis Sci 58:2341\u20132348","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"608_CR31","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ajo.2017.03.002","volume":"177","author":"K Gumus","year":"2017","unstructured":"Gumus K, Schuetzle KL, Pflugfelder SC (2017) Randomized controlled crossover trial comparing the impact of sham or Intranasal tear neurostimulation on conjunctival goblet cell degranulation. Am J Ophthalmol 177:159\u2013168","journal-title":"Am. J. Ophthalmol."},{"key":"608_CR32","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0161-6420(99)90171-9","volume":"106","author":"P Marsh","year":"1999","unstructured":"Marsh P, Pflugfelder SC (1999) Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 106:811\u2013816","journal-title":"Ophthalmology"},{"key":"608_CR33","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ajo.2004.04.052","volume":"138","author":"SC Pflugfelder","year":"2004","unstructured":"Pflugfelder SC, Maskin SL, Anderson B et al (2004) A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5\u202f%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol 138:444\u2013457","journal-title":"Am. J. Ophthalmol."},{"key":"608_CR34","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5001002","author":"C Baudouin","year":"2017","unstructured":"Baudouin C, de la Maza MS, Amrane M et al (2017) One-year efficacy and safety of 0.1\u202f% cyclosporine A cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol. \n                        https:\/\/doi.org\/10.5301\/ejo.5001002","journal-title":"Eur J Ophthalmol"},{"key":"608_CR35","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5301\/ejo.5000779","volume":"26","author":"A Leonardi","year":"2016","unstructured":"Leonardi A, Van Setten G, Amrane M et\u00a0al (2016) Efficacy and safety of 0.1\u202f% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a\u00a0multicenter randomized trial. Eur J Ophthalmol 26:287\u2013296","journal-title":"Eur J Ophthalmol"},{"issue":"127","key":"608_CR36","first-page":"146","volume":"2009","author":"MM Brown","year":"1960","unstructured":"Brown MM, Brown GC, Brown HC, Peet J, Roth Z (1960) Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome. Arch Ophthalmol 2009(127):146\u2013152","journal-title":"Arch Ophthalmol"},{"key":"608_CR37","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1136\/bjophthalmol-2015-306930","volume":"100","author":"M Straub","year":"2016","unstructured":"Straub M, Bron AM, Muselier-Mathieu A, Creuzot-Garcher C (2016) Long-term outcome after topical ciclosporin in severe dry eye disease with a\u00a010-year follow-up. Br J Ophthalmol 100:1547\u20131550","journal-title":"Br J Ophthalmol"},{"key":"608_CR38","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ophtha.2006.05.077","volume":"114","author":"SE Wilson","year":"2007","unstructured":"Wilson SE, Perry HD (2007) Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology 114:76\u201379","journal-title":"Ophthalmology"},{"key":"608_CR39","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/ICO.0000000000000803","volume":"35","author":"ED Donnenfeld","year":"2016","unstructured":"Donnenfeld ED, Karpecki PM, Majmudar PA et al (2016) Safety of Lifitegrast ophthalmic solution 5.0\u202f% in patients with dry eye disease: a 1\u2011year, multicenter, randomized, placebo-controlled study. Cornea 35:741\u2013748","journal-title":"Cornea"},{"key":"608_CR40","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ajo.2011.11.003","volume":"153","author":"CP Semba","year":"2012","unstructured":"Semba CP, Torkildsen GL, Lonsdale JD et al (2012) A phase 2 randomized, double-masked, placebo-controlled study of a\u00a0novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol 153:1050\u20131060.e1","journal-title":"Am. J. Ophthalmol."},{"key":"608_CR41","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","volume":"121","author":"JD Sheppard","year":"2014","unstructured":"Sheppard JD, Torkildsen GL, Lonsdale JD et al (2014) Lifitegrast ophthalmic solution 5.0\u202f% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology 121:475\u2013483","journal-title":"Ophthalmology"},{"key":"608_CR42","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","volume":"122","author":"J Tauber","year":"2015","unstructured":"Tauber J, Karpecki P, Latkany R et al (2015) Lifitegrast ophthalmic solution 5.0\u202f% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study. Ophthalmology 122:2423\u20132431","journal-title":"Ophthalmology"},{"key":"608_CR43","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.transproceed.2005.02.075","volume":"37","author":"H Takeuchi","year":"2005","unstructured":"Takeuchi H, Okuyama K, Konno O et\u00a0al (2005) Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters. Transplant Proc 37:1745\u20131747","journal-title":"Transplant. Proc."},{"key":"608_CR44","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.clae.2015.04.004","volume":"38","author":"BK Moscovici","year":"2015","unstructured":"Moscovici BK, Holzchuh R, Sakassegawa-Naves FE et al (2015) Treatment of Sjogren\u2019s syndrome dry eye using 0.03\u202f% tacrolimus eye drop: prospective double-blind randomized study. Cont Lens Anterior Eye 38:373\u2013378","journal-title":"Cont Lens Anterior Eye"},{"key":"608_CR45","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1167\/iovs.13-12370","volume":"54","author":"A Labbe","year":"2013","unstructured":"Labbe A, Liang Q, Wang Z et al (2013) Corneal nerve structure and function in patients with non-sjogren dry eye: clinical correlations. Invest Ophthalmol Vis Sci 54:5144\u20135150","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"608_CR46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/eye.2014.263","volume":"29","author":"A Galor","year":"2015","unstructured":"Galor A, Levitt RC, Felix ER, Martin ER, Sarantopoulos CD (2015) Neuropathic ocular pain: an important yet underevaluated feature of dry eye. Eye (Lond) 29:301\u2013312","journal-title":"Eye (Lond)"},{"key":"608_CR47","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jtos.2012.01.002","volume":"10","author":"P Rosenthal","year":"2012","unstructured":"Rosenthal P, Borsook D (2012) The corneal pain system. Part I: the missing piece of the dry eye puzzle. Ocul Surf 10:2\u201314","journal-title":"Ocul Surf"},{"key":"608_CR48","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK et\u00a0al (2017) TFOS DEWS II definition and classification report. Ocul Surf 15:276\u2013283","journal-title":"Ocul Surf"},{"key":"608_CR49","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1167\/iovs.08-2716","volume":"50","author":"A Lambiase","year":"2009","unstructured":"Lambiase A, Micera A, Pellegrini G et\u00a0al (2009) In vitro evidence of nerve growth factor effects on human conjunctival epithelial cell differentiation and mucin gene expression. Invest Ophthalmol Vis Sci 50:4622\u20134630","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"608_CR50","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00417-004-0955-2","volume":"243","author":"M Coassin","year":"2005","unstructured":"Coassin M, Lambiase A, Costa N et\u00a0al (2005) Efficacy of topical nerve growth factor treatment in dogs affected by dry eye. Albrecht Von Graefes Arch Klin Exp Ophthalmol 243:151\u2013155","journal-title":"Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"key":"608_CR51","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/sj.eye.6700616","volume":"17","author":"S Bonini","year":"2003","unstructured":"Bonini S, Rama P, Olzi D, Lambiase A (2003) Neurotrophic keratitis. Eye (Lond) 17:989\u2013995","journal-title":"Eye (Lond)"},{"key":"608_CR52","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.exer.2011.06.014","volume":"93","author":"P Jain","year":"2011","unstructured":"Jain P, Li R, Lama T, Saragovi HU, Cumberlidge G, Meerovitch K (2011) An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a\u00a0rat model of dry eye. Exp Eye Res 93:503\u2013512","journal-title":"Exp. Eye Res."},{"key":"608_CR53","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2147\/OPTH.S44688","volume":"7","author":"K Meerovitch","year":"2013","unstructured":"Meerovitch K, Torkildsen G, Lonsdale J et al (2013) Safety and efficacy of MIM-D3 ophthalmic solutions in a\u00a0randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol 7:1275\u20131285","journal-title":"Clin Ophthalmol"},{"key":"608_CR54","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jtos.2013.12.001","volume":"12","author":"D Finis","year":"2014","unstructured":"Finis D, Hayajneh J, Konig C, Borrelli M, Schrader S, Geerling G (2014) Evaluation of an automated thermodynamic treatment (LipiFlow(R)) system for meibomian gland dysfunction: a\u00a0prospective, randomized, observer-masked trial. Ocul Surf 12:146\u2013154","journal-title":"Ocul Surf"},{"key":"608_CR55","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/ICL.0000000000000166","volume":"42","author":"JV Greiner","year":"2016","unstructured":"Greiner JV (2016) Long-Term (3 year) Effects of a\u00a0single thermal pulsation system treatment on meibomian gland function and dry eye symptoms. Eye Contact Lens 42:99\u2013107","journal-title":"Eye Contact Lens"},{"key":"608_CR56","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/ICO.0b013e318239aaea","volume":"31","author":"SS Lane","year":"2012","unstructured":"Lane SS, DuBiner HB, Epstein RJ et\u00a0al (2012) A new system, the LipiFlow, for the treatment of meibomian gland dysfunction. Cornea 31:396\u2013404","journal-title":"Cornea"},{"key":"608_CR57","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1167\/iovs.14-15764","volume":"56","author":"JP Craig","year":"2015","unstructured":"Craig JP, Chen YH, Turnbull PR (2015) Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 56:1965\u20131970","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"608_CR58","first-page":"45","volume":"5","author":"DJ Goldberg","year":"2012","unstructured":"Goldberg DJ (2012) Current trends in intense pulsed light. J\u00a0Clin Aesthet Dermatol 5:45\u201353","journal-title":"J Clin Aesthet Dermatol"},{"key":"608_CR59","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/ICO.0000000000000735","volume":"35","author":"S Vegunta","year":"2016","unstructured":"Vegunta S, Patel D, Shen JF (2016) Combination therapy of Intense Pulsed Light Therapy and Meibomian Gland Expression (IPL\/MGX) can improve dry eye symptoms and meibomian gland function in patients with refractory dry eye: a retrospective analysis. Cornea 35:318\u2013322","journal-title":"Cornea"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-017-0608-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-017-0608-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-017-0608-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T11:10:56Z","timestamp":1518174656000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-017-0608-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,13]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["608"],"URL":"https:\/\/doi.org\/10.1007\/s00347-017-0608-6","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,13]]}}}